References

1. Stienstra Y, van der Graaf WT, Asamoa K et al. Beliefs and attitudes toward Buruli ulcer in Ghana. Am J Trop Med Hyg. 2002;67(2):207-13. PubMed | Google Scholar


2. Vouking MZ, Tamo VC, Tadenfok CN. Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review. Pan Afr Med J. 2013;15:155. PubMed | Google Scholar


3. Etuaful S, Carbonn, Grosset J et al. Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans. Antimicrob Agents Chemother. 2005;49(8):3182-6. PubMed | Google Scholar


4. Etuaful S, Carbonnelle B, Grosset J et al. Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans. Antimicrob Agents Chemother. 2005;49(8):3182-6. PubMed | Google Scholar


5. Amofah G, Bonsu F, Tetteh C et al. Buruli ulcer in Ghana: results of a national case search. Emerg Infect Dis. 2002;8(2):167-70. PubMed | Google Scholar


6. Van der Werf TS, van der Graaf WT, Tappero JW et al. Mycobacterium ulcerans infection. Lancet. 1999;354(9183):1013-8. PubMed | Google Scholar


7. Sarfo FS, Phillips R, Asiedu K et al. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother. 2010;54(9):3678-85. PubMed | Google Scholar


8. Chauty A, Ardant MF, Adeye A et al. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother. 2007;51(11):4029-35. PubMed | Google Scholar


9. Constantine A, Julius YF, Saidu Y. The effectiveness of treatment of Buruli Ulcer with Streptomycin-Rifampicin: A systematic review. JBI Database Syst Rev Implement Rep. 2009;7(8 Suppl):37-46. PubMed | Google Scholar


10. Alferink M, van der Werf TS, Sopoh GE et al. Perceptions on the Effectiveness of Treatment and the Timeline of Buruli Ulcer Influence Pre-Hospital Delay Reported by Healthy Individuals. PLoS Negl Trop Dis. 2013;7(1):e2014. PubMed | Google Scholar


11. GHS. Ghana Health ce: Burul Ulcer Annual Report.2008.. Google Scholar


12. Aiga H, Amano T, Cairncross S et al. Assessing water-related risk factors for Buruli ulcer: a case-control study in Ghana. Am J Trop Med Hyg. 2004;71(4):387-92. PubMed | Google Scholar


13. Amofah G BF, Amofah G, Bonsu F, Tetteh C et al. Buruli ulcer in Ghana: results of a national case search. Emerg Infect Dis. 2002;8(2):167-70. PubMed | Google Scholar


14. Ahoua L, Guetta AN, Ekaza E et al. Risk factors for Buruli ulcer in Côte d?Ivoire: Results of a case-control study, August 2001. Afr J Biotechnol. 2009; 8(4):536-546. PubMed | Google Scholar


15. Ackumey MM, Gyapong M, Pappoe M et al. Socio-cultural determinants of timely and delayed treatment of Buruli ulcer: implications for disease control. Infect Dis Poverty. 2012oct 25;1(1):6. PubMed | Google Scholar


16. Grietens KP, Toomer E, Boock AU et al. What Role Do Traditional Beliefs Play in Treatment Seeking and Delay for Buruli Ulcer Disease?Insights from a Mixed Methods Study in Cameroon. PLOS ONE. 2012;7(5):e36954. PubMed | Google Scholar


17. Dega H, Robert J, Bonnafous P et al. Activities of Several Antimicrobials against Mycobacterium ulcerans Infection in Mice. Antimicrob Agents Chemother. 2000;44(9):2367-72. PubMed | Google Scholar